A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Amantadine (GOCOVRI)

INDICATIONS AND USAGE Amantadine hydrochloride capsules, USP are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus.

First FDA approval1993-06-28
Generic availableYes · 19 mfrs
Shortage statusDiscontinued
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$190.5M in CY2024 Part D spend849K claims · 200K beneficiaries · 329 plans surveyed

Lowest NADAC
$0.051/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.127
Across all dosage forms in distribution.
Highest NADAC
$0.146
Range is tight.
Plans with PA
30 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Amantadine used for?

INDICATIONS AND USAGE Amantadine hydrochloride capsules, USP are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus.

Is there a generic for Amantadine?

Yes. 22 ANDAs filed at FDA, 19 generic manufacturers currently shipping.

How much does my plan pay for Amantadine?

Across 329 Part D plans, Amantadine averages $0.127/unit (NADAC). Lowest available: $0.051/unit. Highest in distribution: $0.146/unit.

Is Amantadine on the FDA shortage list?

Amantadine has been discontinued by its manufacturer(s).

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.